Clearmind Medicine Inc (CMND)

$0.74 +0.01 (1.01%)
Market Cap 1.22M
Revenue (ttm) 0.00
Net Income (ttm) -3.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 791,700
Avg Vol 5,811,484
Day's Range N/A - N/A
Shares Out 1.50M
Stochastic %K 16%
Beta 1.32
Analysts Strong Buy
Price Target N/A

Company Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 536 1016
Address:
1220 West 6th Avenue, Suite 101, Vancouver, Canada
Homer_Simpson82
Homer_Simpson82 Apr. 29 at 8:07 AM
$CMND next trash👌👌. See you under 0.5s next RS
0 · Reply
ZephyrsDrift
ZephyrsDrift Apr. 28 at 9:35 PM
Ticker BTBD 🚨 keep eyes on this one, starting to breakout! Huge news: Aero Velocity (merger partner) partnered with AC Future to develop a Mobile Drone Launch Vehicle (MDLV) platform for U.S. military and public-sector use in contested environments. Drones Plays a major role now days in any war, BTBD is a total gem! This is a huge opportunity to get in on BTBD early! $ALP $USE g$SGMT $CMND ww....a11
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:28 PM
$ATER DONT CHASE !!!! $CMND IS NEXXXTTTTTT
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:27 PM
$CMND $SEGG $AKAN THE CHART AT $CMND DONT LIE !!! NEXT ONE TO POP OVER $1+++
1 · Reply
Hfaistos
Hfaistos Apr. 28 at 7:11 PM
$CMND I hope you’re right!
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:10 PM
$AKAN NEXTTT RUNNNNERRR IS $CMND
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:10 PM
$ATER $SEGG NEXT RUNNERRR IS $CMND LFGGGG BULLLSSS
0 · Reply
BankingBig
BankingBig Apr. 28 at 6:19 PM
$CMND well there is that. But I want over .75 here
0 · Reply
prettyboystocks
prettyboystocks Apr. 28 at 6:10 PM
$CMND I bought in at 1.03 n . 81 so I'm waiting for it to blow up. It's tied to the Trump executive order, they will play a factor in it.
0 · Reply
Homer_Simpson82
Homer_Simpson82 Apr. 28 at 5:51 PM
$SEGG $CYCU $CMND no newss
1 · Reply
Latest News on CMND
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 27, 2026, 7:41 AM EDT - 1 day ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 4:03 PM EDT - 8 days ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Why Is Clearmind Stock Rising Monday?

Apr 20, 2026, 9:39 AM EDT - 8 days ago

Why Is Clearmind Stock Rising Monday?

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Apr 20, 2026, 7:15 AM EDT - 8 days ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Apr 15, 2026, 7:30 AM EDT - 13 days ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Apr 14, 2026, 7:32 AM EDT - 14 days ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Mar 30, 2026, 8:32 AM EDT - 4 weeks ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Mar 27, 2026, 7:32 AM EDT - 4 weeks ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 19, 2026, 8:45 AM EDT - 5 weeks ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 17, 2026, 9:15 AM EDT - 6 weeks ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 7:30 AM EDT - 6 weeks ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 6 weeks ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 9:07 AM EDT - 6 weeks ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 11, 2026, 7:30 AM EDT - 6 weeks ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 7 weeks ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Mar 4, 2026, 7:30 AM EST - 7 weeks ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 19, 2026, 1:05 PM EST - 2 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 9, 2026, 8:17 AM EST - 2 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 6, 2026, 7:55 AM EST - 2 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Feb 3, 2026, 8:00 AM EST - 3 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 4:20 PM EST - 3 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Jan 14, 2026, 8:55 AM EST - 3 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 31, 2025, 9:10 AM EST - 4 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 24, 2025, 9:15 AM EST - 4 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 16, 2025, 8:45 AM EST - 4 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 8:32 AM EST - 4 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 12, 2025, 6:32 AM EST - 4 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 10, 2025, 4:15 PM EST - 4 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 5:00 PM EST - 5 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 2, 2025, 7:57 AM EST - 5 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Dec 1, 2025, 8:56 AM EST - 5 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 25, 2025, 7:17 AM EST - 5 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 24, 2025, 8:51 AM EST - 5 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 20, 2025, 6:01 AM EST - 5 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 5 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 18, 2025, 8:56 AM EST - 5 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 17, 2025, 7:55 AM EST - 5 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 13, 2025, 8:54 AM EST - 5 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 12, 2025, 6:25 AM EST - 5 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 10, 2025, 8:07 AM EST - 6 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 6, 2025, 4:02 PM EST - 6 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Nov 5, 2025, 6:55 AM EST - 6 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 30, 2025, 7:55 AM EDT - 6 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Oct 28, 2025, 8:08 AM EDT - 6 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Oct 27, 2025, 9:22 AM EDT - 6 months ago

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 21, 2025, 7:25 AM EDT - 6 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 6 months ago

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Sep 25, 2025, 7:40 AM EDT - 7 months ago

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Sep 19, 2025, 8:20 AM EDT - 7 months ago

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 9 months ago

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Homer_Simpson82
Homer_Simpson82 Apr. 29 at 8:07 AM
$CMND next trash👌👌. See you under 0.5s next RS
0 · Reply
ZephyrsDrift
ZephyrsDrift Apr. 28 at 9:35 PM
Ticker BTBD 🚨 keep eyes on this one, starting to breakout! Huge news: Aero Velocity (merger partner) partnered with AC Future to develop a Mobile Drone Launch Vehicle (MDLV) platform for U.S. military and public-sector use in contested environments. Drones Plays a major role now days in any war, BTBD is a total gem! This is a huge opportunity to get in on BTBD early! $ALP $USE g$SGMT $CMND ww....a11
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:28 PM
$ATER DONT CHASE !!!! $CMND IS NEXXXTTTTTT
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:27 PM
$CMND $SEGG $AKAN THE CHART AT $CMND DONT LIE !!! NEXT ONE TO POP OVER $1+++
1 · Reply
Hfaistos
Hfaistos Apr. 28 at 7:11 PM
$CMND I hope you’re right!
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:10 PM
$AKAN NEXTTT RUNNNNERRR IS $CMND
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 7:10 PM
$ATER $SEGG NEXT RUNNERRR IS $CMND LFGGGG BULLLSSS
0 · Reply
BankingBig
BankingBig Apr. 28 at 6:19 PM
$CMND well there is that. But I want over .75 here
0 · Reply
prettyboystocks
prettyboystocks Apr. 28 at 6:10 PM
$CMND I bought in at 1.03 n . 81 so I'm waiting for it to blow up. It's tied to the Trump executive order, they will play a factor in it.
0 · Reply
Homer_Simpson82
Homer_Simpson82 Apr. 28 at 5:51 PM
$SEGG $CYCU $CMND no newss
1 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 5:38 PM
$SEGG $CYCU FDAAA NEWWWSSS AT $CMND
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 5:25 PM
$SEGG $CYCU CUP AND HANDLE AT $CMND NEXT RUNNERRR 🏃
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 4:36 PM
$SMX BIG BOUNCE AT $CMND
0 · Reply
PicassoGalileo
PicassoGalileo Apr. 28 at 4:35 PM
$SEGG NEXT ONE UP IS $CMND
0 · Reply
BankingBig
BankingBig Apr. 28 at 3:45 PM
$CMND big support at .70 always bounces off there. Nothing more than that imo
0 · Reply
BankingBig
BankingBig Apr. 28 at 3:44 PM
$CMND think we going green here shortly. Let's see .80 again
0 · Reply
Dumbull77
Dumbull77 Apr. 28 at 3:34 PM
$CMND Weird chatrt, looks like a group decided to enter to or cover right at 0.70
0 · Reply
Jbjb90
Jbjb90 Apr. 28 at 2:23 PM
$CMND added small down here https://www.stocktitan.net/news/CMND/clearmind-medicine-announces-evaluation-of-its-psychedelic-based-j2hjzbmcn7f1.html
0 · Reply
Jbjb90
Jbjb90 Apr. 28 at 2:17 PM
$CMND
0 · Reply
BankingBig
BankingBig Apr. 28 at 1:34 PM
$CMND just patiently waiting for those .696s to fill!
0 · Reply
LS815
LS815 Apr. 28 at 12:09 PM
$CMND well looks like everyone left 🤣🤣
0 · Reply
BioRich
BioRich Apr. 28 at 2:36 AM
$CMND Best of luck. We made massive money here (if you bought recently) but I'm gonna have to sit this one out moving forward. I think SP will pull back to pre-Trump announcement within the next 2 weeks (if not the next 2 days). I just see a few other options that I believe can make better returns in the near future. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply